Revolutionizing Lung Cancer Detection: The Role of AI-Derived CAD Software

By HEOR Staff Writer

July 12, 2023

Artificial Intelligence (AI)-derived computer-aided detection (CAD) software may be a game-changer in the field of lung cancer screening. These technologies can potentially enhance the detection and measurement of lung nodules in CT scan images, making them a cost-effective solution. However, more evidence is needed to ascertain which technologies are the most clinically and cost-effective.

There is little clinical-effectiveness evidence available on any of the individual technologies which means that more research is needed to fully understand the potential benefits and drawbacks of these technologies. For example, the software could potentially identify more people with benign lung nodules, leading to unnecessary anxiety and CT surveillance. 

Despite these uncertainties, the potential benefits of AI-derived CAD software cannot be ignored. Not only can it potentially increase the detection of lung nodules, but it can also improve reporting of nodule characteristics, assess the growth of lung nodules, and reduce the time to review and report CT scans. 

NICE encourages centres using AI-derived CAD software as part of targeted lung cancer screening to continue generating evidence and sharing their findings. This will help to realise the full potential of these technologies and facilitate comparisons between different software.

Recommendations for further research on the effect of using the software on clinical decision making and the effect of using the software on scan review and reporting time, are listed in the guideline.

Reference url

Recent Posts

OTC Glucose Monitoring Children
Regulatory Expansion of OTC Glucose Monitoring for Children

By João L. Carapinha

June 15, 2026

The FDA has cleared the first over-the-counter continuous glucose monitor for children as young as two who do not use insulin, establishing OTC Glucose Monitoring Children as a practical new option for families. This
FDA Medical Device Exemptions
FDA Medical Device Exemptions for Low-Risk Unclassified Products

By HEOR Staff Writer

June 15, 2026

The FDA Medical Device Exemptions target specific unclassified preamendment devices that present minimal risk to patients. By exercising enforcement discretion, the agency no longer expects manufacturers to submit 510(k) premarket notification applications for these products until a formal exempt...
medtech reimbursement strategies
Navigating Medtech Reimbursement Strategies for Successful Innovation

By João L. Carapinha

June 15, 2026

Successful medtech reimbursement strategies must be developed in parallel with regulatory approval, because clearance only confirms safety and efficacy while payers separately decide financial coverage. Investors now routinely demand evidence of sustainable payment pathways long before regulatory...